A stress-induced early innate response causes multidrug tolerance in melanoma

Oncogene

Volumn 34, Issue 34, 2015, Pages 4448-4459

  Menon, D Ravindran ^a,b   Das, S ^a   Krepler, C ^c   Vultur, A ^c   Rinner, B ^a   Schauer, S ^a   Kashofer, K ^a   Wagner, K ^a   Zhang, G ^c   Bonyadi Rad, E ^a   Haass, N K ^b   Soyer, H P ^b   Gabrielli, B ^b   Somasundaram, R ^c   Hoefler, G ^a   Herlyn, M ^c   Schaider, H ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ALDEHYDE DEHYDROGENASE; CISPLATIN; DOCETAXEL; FLUOROURACIL; HISTONE DEMETHYLASE; MELAN A; MONOPHENOL MONOOXYGENASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; TRAMETINIB; VEMURAFENIB; KDM5B PROTEIN, HUMAN; NERVE GROWTH FACTOR RECEPTOR; NERVE PROTEIN; NGFR PROTEIN, HUMAN; NUCLEAR PROTEIN; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE MANAGEMENT; DRUG EXPOSURE; DRUG TOLERANCE; GENE REPRESSION; HUMAN; HUMAN CELL; HYPOXIA; INNATE IMMUNITY; LOW DRUG DOSE; MELANOMA; MELANOMA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUTRIENT; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; STRESS; UPREGULATION; WESTERN BLOTTING; ANIMAL; DRUG RESISTANCE; PHYSIOLOGICAL STRESS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MELANOMA; MICE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PYRIDONES; PYRIMIDINONES; RECEPTORS, NERVE GROWTH FACTOR; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 84939777359     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.372     Document Type: Article

References (34)

1. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
2. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-977.
3. Das TM, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-255.
4. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
5. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141: 583-594.
6. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 2013; 23: 811-825.
7. Haass NK, Beaumont KA, Hill DS, Anfosso A, Mrass P, Munoz MA et al. Real-time cell cycle imaging during melanoma growth, invasion, and drug response. Pigment Cell Melanoma Res 2014; 27: 764-776.
8. Shakhova O, Sommer L. Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. Cancer Lett 2013; 338: 74-81.
9. Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 2013; 23: 768-783.
10. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005; 65: 4320-4333.
11. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11: 3067-3078.
12. Elliott AM, Al-Hajj MA. ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res 2009; 7: 79-87.
13. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004; 3: 833-838.
14. Chen YT, Stockert E, Jungbluth A, Tsang S, Coplan KA, Scanlan MJ et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93: 5915-5919.
15. Kwon BS. Pigmentation genes: the tyrosinase gene family and the pmel 17 gene family. J Invest Dermatol 1993 100(2 Suppl): 134S-140S.
16. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 2008; 3: 237-246.
17. Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res 2014; 74: 3579-3590.
18. Koch CM, Andrews RM, Flicek P, Dillon SC, Karaöz U, Clelland GK et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res 2007; 17: 691-707.
19. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
20. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011; 19: 11-15.
21. Huang PH, Chen CH, Chou CC, Sargeant AM, Kulp SK, Teng CM et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol 2011; 79: 197-206.
22. Khalil A, Morgan RN, Adams BR, Golding SE, Dever SM, Rosenberg E et al. ATMdependent ERK signaling via AKT in response to DNA double-strand breaks. Cell Cycle 2011; 10: 481-491.
23. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002; 7: d376-d389.
24. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 1996; 16: 977-989.
25. Zou L, Cao S, Kang N, Huebert RC, Shah VH. Fibronectin induces endothelial cell migration through beta1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766. J Biol Chem 2012; 287: 7190-7202.
26. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-12410.
27. Glover S, Delaney M, Dematte C, Kornberg L, Frasco M, Tran-Son-Tay R et al. Phosphorylation of focal adhesion kinase tyrosine 397 critically mediates gastrin-releasing peptide's morphogenic properties. J Cell Physiol 2004; 199: 77-88.
28. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6: 587-595.
29. Haughian JM, Reno EM, Thorne AM, Bradford AP. Protein kinase C alphadependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer 2009; 125: 2556-2564.
30. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683-695.
31. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490: 412-416.
32. Furuta J, Inozume T, Harada K, Shimada S. CD271 on melanoma cell is an IFNgamma-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol 2014; 134: 1369-1377.
33. Das TM, Stuart DD. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res 2013; 73: 6106-6110.
34. Cvitic S, Longtine MS, Hackl H, Wagner K, Nelson MD, Desoye G, Hiden U. The human placental sexome differs between trophoblast epithelium and villous vessel endothelium. PloS one 2013; 8: e79233.